BRCA1
- Aliases
-
- BRCA1
- BRCA1/BRCA2-containing complex, subunit 1
- BRCAI
- BRCC1
- BROVCA1
- EC 6.3.2.-
- IRIS
- PNCA4
- PPP1R53
- PSCP
- RING finger protein 53
- RNF53
- breast and ovarian cancer susceptibility protein 1
- breast and ovarian cancer sususceptibility protein 1
- breast cancer 1, early onset
- breast cancer type 1 susceptibility protein
- protein phosphatase 1, regulatory subunit 53
- Description
- BRCA1 is a nuclear phosphoprotein that functions as a tumor suppressor. BRCA1 combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). BRCA1 associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers.
Attributes
- QA State
- Curated
- Type
- Protein
- HGNC Name
- BRCA1
- Certifications
-
- None
- QA State for Breast
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Certifications
-
- None
- QA State for Ovary
- Under Review
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.
- Development and validation of sandwich ELISA microarrays with minimal assay interference.
- Discovery and preliminary confirmation of novel early detection biomarkers for triple-negative breast cancer using preclinical plasma samples from the Women's Health Initiative observational study.
- Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased.
Non-Public Biomarker
Organ-specific information for this biomarker is currently being annotated or is "under review". Logging in may give you privileges to view additional information. Contact the Informatics Center if you believe you should have access.